A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF NIVOLUMAB COMBINED WITH IPILIMUMAB VERSUS STANDARD OF CARE CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED UNRESECTABLE OR METASTATIC UROTHELIAL CANCER
- Registry ID
- CA209-901
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- BRISTOL-MYERS SQUIBB CANADA
- Start date
- 2017-11-16
- Last update
- 2017-02-06
Conditions
Related clinical trials
- A PHASE III, OPEN-LABEL, RANDOMISED, MULTICENTRE, GLOBAL STUDY OF ADJUVANT DATOPOTAMAB DERUXTECAN IN COMBINATION WITH RILVEGOSTOMIG IN PARTICIPANTS WITH HIGH-RISK MUSCLE INVASIVE UROTHELIAL CARCINOMA (TROPION-UROTHELIAL04)
- A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF SACITUZUMAB TIRUMOTECAN (MK-2870) CARCINOMA VERSUS INVESTIGATOR’S CHOICE OF NON-PLATINUM CHEMOTHERAPY IN PARTICIPANTS WITH PRETREATED LOCALLY ADVANCED/METASTATIC UROTHELIAL
- IZABRIGHT-BLADDER01: A RANDOMIZED, OPEN-LABEL, PHASE 2/3 TRIAL OF IZALONTAMAB
BRENGITECAN VERSUS PLATINUM-BASED CHEMOTHERAPY FOR METASTATIC UROTHELIAL CANCER
IN PARTICIPANTS WITH DISEASE PROGRESSION ON OR AFTER AN IMMUNOTHERAPY-BASED TREATMENT
- A PHASE 1/2, SINGLE-ARM, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF NADOFARAGENE FIRADENOVEC INSTILLED TO THE RENAL PELVIS IN ADULT SUBJECTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC)
- MODERN: AN INTEGRATED PHASE 2/3 AND PHASE 3 TRIAL OF MRDBASED OPTIMIZATION OF ADJUVANT THERAPY IN UROTHELIAL
CANCER
- A RANDOMIZED OPEN-LABEL PHASE 2/3 STUDY OF BT8009 AS MONOTHERAPY OR IN
COMBINATION IN PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL
CANCER (DURAVELO-2)
View on source registry